Augmenix

Category Archives

Augmenix Announces Positive Clinical Trial Results Demonstrating Efficacy Of Spaceoar Hydrogel In Patients Undergoing Dose-Escalated Stereotactic Body Radiation Therapy For Prostate Cancer

Application of SpaceOAR hydrogel significantly reduces rectal injury in a high-dose SBRT treated patient population BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Augmenix to Unveil New Clinical Data on its Innovative Absorbable Hydrogel Technology at the 59th Annual Meeting of the American Society for Radiation Oncology

BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Inc., a medical technology company that develops, manufactures and sells proprietary absorbable hydrogels that Read more...

Augmenix Ranked as One of America’s Fastest-Growing Private Companies for Second Year

Augmenix Maintains Spot in Top 10% of Metro-Boston Companies; Three-Year Growth over 2,000% Ranked Company Number 207 on Inc. Magazine’s Top 500 BEDFORD, Read more...

Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in Canada

Princess Margaret Cancer Centre to initiate a 20-patient pilot study to assess hydrogel spacer to reduce rectal toxicity during prostate cancer radiation Read more...

Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment

Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...

Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that Read more...

Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material

The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR®technology WALTHAM, Mass.--(BUSINESS Read more...

Augmenix Ranked as One of America’s Fastest-Growing Private Companies

Augmenix Ranked as One of America’s Fastest-Growing Private Companies With a Three-Year Sales Growth of 643%, Augmenix is one of the Fastest Growing Read more...

Augmenix raises $6m in Series E round

Augmenix said today it raised $6 million in a Series E round of funding to support the development of next-gen products and support the Read more...

Augmenix’ SpaceOAR® System Experiences Rapid U.S. Adoption

WALTHAM, Mass.--(Business Wire)--Augmenix, Inc., a privately held company developing minimally invasive hydrogel products to improve outcomes following Read more...

Page 1 of 3123

Contact Info

info@catalysthealthventures.com

(781) 228-5228

50 Braintree Hill Office Park
Suite 301
Braintree, MA 02184